Can Macquarie Telecom (ASX: MAQ) become the next NextDC?

With heavy investment in expanding its data centre capacity, could the Macquarie Telecom share price one day become the next NextDC?

| More on:

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Data warehouse operator Nextdc Ltd (ASX: NXT) sometimes seems like the forgotten sibling of the WAAAX companies – the Tiffany to their Ivanka. But while Afterpay Ltd (ASX: APT) and co hog the media spotlight, NextDC diligently goes about growing its business. And notching up stellar financial results.

NextDC shrugged off the effects of COVID-19 to deliver earnings at the upper end of guidance for FY20. Total revenue grew 14% year-on-year to $205.2 million, while underlying earnings before interest, tax, depreciation and amortisation expenses (EBITDA) shot up 23% to $104.6 million. Not only that, but with a market cap now exceeding $5 billion, NextDC has broken into the ASX top 100.

But as Yoda famously stated: “There is another”. By focussing on the success of NextDC, we might be downplaying the exploits of another growing ASX data warehouse company, Macquarie Telecom Group Ltd. (ASX: MAQ) – the Eric to NextDC’s Don Jr, to keep the Trump analogy going.

About the Macquarie Telecom share price

Macquarie started out positioning itself as a telecommunications rival to Telstra Corporation Ltd (ASX: TLS), particularly for medium sized businesses and government. It has since grown into a diversified technology and communications business with four core segments. These include cloud services, government, telecom and data centres.

Its data centre business has notched up an impressive list of clientele, including the Department of Foreign Affairs and Trade, as well as ASX-listed Westpac Banking Corp (ASX: WBC) and News Corporation (ASX: NWS).

Macquarie’s full year revenue for FY20 was $266.2 million, a year-on-year increase of 8%. EBITDA rose 25% to $65.2 million. Despite a lower EBITDA, this result compares quite favourably against NextDC.  While NextDC posted an overall net loss after tax of $45.2 million for FY20, the Macquarie Group was profitable by $13.5 million.

Macquarie will massively ramp up investment in its data centre operations in FY21. It plans to invest up to $85 million next year to complete its Macquarie Intellicentre 3 East data centre This will almost triple the group’s data centre capacity from 10MW to 28MW.

Keep in mind that this is dwarfed by the $400 million NextDC plans to spend in FY21 expanding its data centre infrastructure. But it shows that Macquarie sees a strategic commercial opportunity in the data centre space. Macquarie also plans to start reporting its Data Centres business as a separate segment from FY21 onwards, showing the confidence it has in the success of this area of its operations.

Should you invest?

As an under-the-radar player in the data centre space, there is plenty to recommend about Macquarie. It is a well-diversified business with a high net promoter score, indicating a loyal customer base. As it targets mid-sized businesses and government, there may also be room for it to grow without needing to battle outsized rival NextDC.

However, the Macquarie Telecom share price has skyrocketed this year – up almost 100% to $45.80 as at the time of writing. FY21 is an investment year for the company, so there could be some pullback in its share price over the next 12 months as capital expenditure puts pressure on EBITDA, particularly over the second half. But if it can deliver on its growth potential, Macquarie may be a great company to own for FY22 and beyond.

Rhys Brock owns shares of AFTERPAY T FPO and NextDC. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of AFTERPAY T FPO. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Rival hands reaching upward for a company trophy or prize.
Share Market News

Here are the top 10 ASX 200 shares today

These ASX 200 shares outperformed all their peers on Friday.

Read more »

A woman sits on sofa pondering a question.
Energy Shares

Is the AGL share price in the buy zone following the company’s latest results?

Are AGL Energy shares worth a post-earnings look?

Read more »

A white and black clock with the words Time to Buy in blue lettering representing the views of two experts who say it's time to buy these ASX shares
Broker Notes

Brokers name 3 ASX shares to buy today

Brokers are bullish on these ASX shares...

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why AGL, Fisher & Paykel, Inghams, and TPG shares are sinking today

These ASX shares are falling heavily on Friday...

Read more »

a woman holds her hands to her temples as she sits in front of a computer screen with a concerned look on her face.
Bank Shares

What’s moving the CBA share price this week?

CommBank shares traded ex-dividend on Wednesday this week.

Read more »

A woman stands on the roof of a city building as papers fly in the sky around her.
Share Market News

Here are the 3 most heavily traded ASX 200 shares on Friday

We take a look at the most traded ASX 200 shares today...

Read more »

A young woman wearing overalls and a yellow t-shirt kicks one leg in the air showing excitement over the latest ASX 200 shares to hit 52-week highs
Share Gainers

Why Accent, Cochlear, Newcrest, and Santos shares are charging higher today

These ASX shares are ending the week strongly...

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Share Gainers

This ASX healthcare company just got FDA approval, and its share price is soaring 18%

Invex Therapeutics is exciting the market today after announcing some big news.

Read more »